awmsg logo



aztreonam lysine (Cayston®)


Reference No. 1715

Publication date:
22/05/2013


Last review date:
30/09/2016

Appraisal information

aztreonam lysine (Cayston®) 75 mg powder and solvent for nebuliser solution


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 20/02/2013
AWMSG meeting date: 20/03/2013
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0613
Ministerial ratification: 22/05/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Aztreonam lysine (Cayston®) is recommended as an option for restricted use within NHS Wales. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Aztreonam lysine (Cayston®) should be restricted for third-line use in the following subpopulation within its licensed indication for suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older: • Patients in whom nebulised colistimethate sodium and nebulised tobramycin are not tolerated or are not providing satisfactory therapeutic benefit. Aztreonam lysine (Cayston®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download